Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. - Abstract - Europe PMC
Early Alectinib Resistance From MET Amplification in ALK Rearranged NSCLC: Response to Crizotinib with Re-response to Alectinib and Crizotinib - Clinical Lung Cancer
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
MET amplification increases the metastatic spread of EGFR-mutated NSCLC - Lung Cancer
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.,Cancer Science - X-MOL
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
FISH analysis of de novo MET amplification in advanced NSCLC and... | Download Scientific Diagram
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Populatio | OTT
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target - ScienceDirect
EGFR pathway in NSCLC. Mutations, amplification or overexpression of... | Download Scientific Diagram
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
new-molecular-drivers-in-nsclc-the-role-of-met
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Figure 6 from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer | Semantic Scholar
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
